Zephyr AI Raises $111 Million in Series A Financing

Latest Investment Will Support the Democratization of Precision Medicine Through the Advancement of Novel Explainable AI Algorithms Zephyr AI, Inc. (Zephyr AI), a healthcare technology company committed to developing fast and explainable Artificial Intelligence (AI) solutions to democratize precision medicine, today announced it has successfully closed a $111 million Series A funding round with participation from Revolution Growth, Eli Lilly & Company, Jeff Skoll, and EPIQ Capital Group, among others. The company is developing improved data federation tools along with various machine learning algorithms in the areas of oncology and cardiometabolic disease. “The US has the highest rate of avoidable cancer and cardiometabolic-related deaths among any high-income country. We must do better,” said Grant Verstandig, Zephyr AI’s Co-Founder and Executive Chairman. “At Zephyr AI, we are harnessing the power of AI to extract novel insights to better define patient stratification and response predictions as well as improve federation of real-world data. With our world-class team and the support of this investor group, we are deploying one of the largest clinicogenomic datasets that has unprecedented breadth across disease states and data partners. Collectively, we are now well positioned to support our mission of democratizing precision medicine, enhancing both the speed and success of clinical trials.” According to Dr. Justin Stebbing, Chairman of Zephyr AI’s Scientifi...
Source: EMR and HIPAA - Category: Information Technology Authors: Tags: Health IT Company Healthcare IT Cooley LLP Dr. Justin Stebbing Eli Lilly & Company EPIQ Capital Group Grant Verstandig Health IT Funding Health IT Fundings Health IT Investment Jeff Sherman Jeff Skoll Oncogene Revolution Growth Source Type: blogs